The clock is ticking—and “true generic” timing is where deals are won or lost.
In pharma, everyone talks about exclusivity. Fewer people map it with the precision required to hit the market window for a true generic entry—especially when multiple regul…
Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…
Generic competition doesn’t just change prices—it redraws the map of who gets paid, who gets blocked, and how long patients wait.
That’s the real story behind Paragraph IV challenges and “pay-for-delay” settlements—an ecosystem where litigation strat…
Consumers don’t just pay for medicine. They pay for certainty.
That’s the uncomfortable truth behind “branded generics”—a category that often gets dismissed as a marketing relic, when in reality it reflects a deeper economic reality: when patients and …
Why Consumers Pay a “Trust Premium” for Branded Generics Read Post »
AI is no longer “about” your drug. It’s about your competitive position.
Drug developers have spent years optimizing molecules, trials, and manufacturing—then quietly treating competitive intelligence as a separate workflow. But the reality is shifti…
What AI Knows About Your Drug vs. Your Competitors Read Post »
Most pharma teams don’t lose because they lack data. They lose because they don’t see the right data at the right time.
That’s the uncomfortable truth behind the “intelligence gap” many companies quietly live with—especially when it comes to patent str…
Read the Patent, Beat the Competition: The Intelligence Gap Most Pharma Teams Leave Open Read Post »
Two systems. One fight. How the “patent dance” and Orange Book linkage are shaping the $400B biologics war.
The biologics market is no longer just a science story—it’s a timing story.
At stake is a staggering number: $400 billion in biologics revenue, …
Most teams don’t lose because they miss a breakthrough—they lose because they miss a deadline.
In pharma, timing is everything. A single overlooked patent expiration can turn a “defensive” strategy into a scramble, a launch plan into a lawsuit, and a r…
Find Expired Drug Patents Before Your Competitors Do Read Post »
The real fight doesn’t start when the patent is granted—it starts when it’s about to expire.
For years, the pharmaceutical playbook has been framed as a straight line: patent protection buys time, generic entry follows, and everyone moves on. But the m…
AI is your drugs’ new KOL—and you’re not tracking it.
That’s the uncomfortable truth buried in the latest DrugPatentWatch post: as artificial intelligence becomes embedded in how clinicians, researchers, and even patients find information, it’s quietly…
AI Is Your Drug’s New KOL — and You’re Not Tracking It Read Post »
Get new actionable insights and updates from BiotechBlog
